LYEL Lyell Immunopharma, Inc.
$15.43+43.27%
Last close: · regular session · Last 60 sessions
After-hours $15.74 +2.01% ·
LYEL dilution and offerings
S-3 shelf filed Jul 2026: it registers shares the company can sell later.
- Float
- 8.8M
- Shelf
- S-3
- Last filing
- 10-Q · Nov 4, 2026
Latest SEC filings for LYEL
| 10-Q | Quarterly report | |
| 8-K | Current report | |
| 8-K | Current report | |
| 10-Q | Quarterly report | |
| 8-K | Current report | |
| EFFECT | ||
| S-3 | Shelf — dilutive | |
| S-3 | Shelf — dilutive | |
| 8-K | Current report | |
| 10-Q | Quarterly report |
Dilution today: new offering filings and reverse splits
Active shelf registration (S-3, Jul 2026). Float: 8.8M shares. Latest SEC filing: 10-Q on Nov 4, 2026. LYEL closed at $15.43 (+43.27%) on Nov 4, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for LYEL in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 300
- Website: https://www.lyell.com
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Latest LYEL news
- Lyell Immunopharma reports Q3 results Read article
- Lyell Immunopharma raises $80M in private placement; shares up 35% Read article
- Down 27% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround Read article
Recent dilution filers
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.